1.Unstableanginapectorisandnon-STsegmentelevationmyocardialinfarction:subcutaneousinjection120U/kg(maximumdose10000U),twiceaday,continuefor5-8daysoruntiltheconditionisstable,andtakeaspirinatthesametim
1.APTTTheHeparinsManufacturerdescribesAPTTasstilloneoftheoptionsformonitoringUFH.Itisverysimple,fastandcheapproject.However,itisdifficulttostandardize.TheAPTTtestrequiresthatallproteinsintheentireclot
1,performancedifferencesLowmolecularweightheparinisakindoflowmolecularweightheparinpreparedbydepolymerizationofgeneralheparin.Itspharmacodynamicsandpharmacokineticcharacteristicsaredifferentfromthoseo
Properties:Whiteoralmostwhitepowder;Slightlysalty;Odourless;Itishygroscopic.Theaqueoussolutionofthisproductisviscousanddoesnotcondensewhenheated.Thisproductiseasytodissolveinwater,notinethanol,acetone